AbbVie: Rinvoq Hits AD Treat-to-Target Aims as Early as Week 2

Treatment with Rinvoq® (upadacitinib) 15mg or 30mg allows patients to rapidly achieve their initial three-month acceptable treatment target goal at Week 2, with consistent achievement through Week 16, results of a new analysis show. Using the framework of the recently developed evidence-based treat-to-target framework, researchers compared outcomes for upadacitinib versus placebo from the Measure Up 1 and Measure Up 2 trials.

Additionally, analysis shows that the majority of patients treated with upadacitinib 15mg or 30mg rapidly achieved the more stringent six-month optimal target goal at Week 2, with similar results seen at Week 16. Results were presented in poster format at the 2022 American Academy of Dermatology (AAD) Annual Meeting in Boston.

In all, AbbVie presented 12 abstracts and two late-breaking presentations during the AAD meeting. Data across AbbVie and Allergan's diversified portfolio of medical and aesthetic dermatology products underscore the companies' deep-rooted commitment to advancing science and striving to redefine the standards of patient care, the companies say.

A post-hoc analysis from the Heads Up study evaluating the degree and distribution of skin improvement from baseline with Rinvoq® versus Dupixent® (dupilumab) in adults with moderate to severe atopic dermatitis show a greater proportion of patients (59%) achieved incrementally greater skin improvement thresholds at week 16 with upadacitinib versus dupilumab. At week 16, greater proportions of patients with moderate-to-severe AD achieved higher thresholds of skin improvement with upadacitinib versus dupilumab, which may translate to improvements in overall patient QoL.

An interim analysis from the LIMMitless open-label extension trial investigating continuous Skyrizi® (risankizumab-rzaa) treatment beyond 4.5 years in adults with moderate to severe plaque psoriasis, shows that long-term treatment up to 256 weeks once every 12 weeks provides high durable efficacy response and sustained improvements in health-related quality of life for patients. Overall, long-term continuous RZB treatment is well tolerated, with no new safety signals noted through more than 5.5 years of continuous exposure.